10.6084/m9.figshare.5630065
Maj-Britt Jensen
Maj-Britt
Jensen
Torsten O. Nielsen
Torsten
O. Nielsen
Ann S. Knoop
Ann
S. Knoop
Anne-Vibeke Laenkholm
Anne-Vibeke
Laenkholm
Eva Balslev
Eva
Balslev
Bent Ejlertsen
Bent
Ejlertsen
Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials
Taylor & Francis Group
2017
loco-regional treatment
DBCG 77 trials Background
HER 2-positive
35 years
2E
background population
DBCG 77 trials
tumor size
prognostic subsets
mortality rate
PR
MFP
patient characteristics
subtype classification
histological type
HER 2. Intrinsic subtypes
risk patients
Core basal
axillary nodes
multivariate model
November 1977
5 cm
mortality rates
prognostic score
breast cancer
Ki
clinicopathologic characteristics
immunohistochemistry panels
recurrence rates
EGFR
risk breast cancer patients
Archival tumor tissue
nodal status
2017-11-23 12:17:12
Journal contribution
https://tandf.figshare.com/articles/journal_contribution/Mortality_and_recurrence_rates_among_systemically_untreated_high_risk_breast_cancer_patients_included_in_the_DBCG_77_trials/5630065
<p><b>Background:</b> Following loco-regional treatment for early breast cancer accurate prognostication is essential for communicating benefits of systemic treatment. The aim of this study was to determine time to recurrence and long-term mortality rates in high risk patients according to patient characteristics and subtypes as assigned by immunohistochemistry panels.</p> <p><b>Patients and methods:</b> In November 1977 through January 1983, 2862 patients with tumors larger than 5 cm or positive axillary nodes were included in the DBCG 77 trials. Archival tumor tissue from patients randomly assigned to no systemic treatment was analyzed for ER, PR, Ki67, EGFR and HER2. Intrinsic subtypes were defined as follows: Luminal A, ER or PR >0%, HER2-negative, PR >10% and Ki67 < 14%; Luminal B, ER or PR >0%, (PR ≤10% or HER2-positive or Ki67 ≥ 14%); HER2E, ER 0%, PR 0%, HER2 positive; Core basal, ER 0%, PR 0%, HER2 negative and EGFR positive. Multivariate categorical and fractional polynomials (MFP) models were used to construct prognostic subsets by clinicopathologic characteristics.</p> <p><b>Results:</b> In a multivariate model, mortality rate was significantly associated with age, tumor size, nodal status, invasion, histological type and grade, as well as subtype classification.</p> <p><b>Conclusions:</b> With 35 years of follow-up, in this population of high-risk patients with no systemic therapy, no subgroup based on a composite prognostic score and/or molecular subtypes could be identified without excess mortality as compared to the background population.</p>